Topics

Mid-stage study of AnaptysBio's anti-IL-33 antibody etokimab in atopic dermatitis fails to hit main goal https://www.firstwordpharma.com/node/1679605  $ANAB

08:20 EST 8 Nov 2019 | FirstWord Pharma

Mid-stage study of AnaptysBio's anti-IL-33 antibody etokimab in atopic dermatitis fails to hit main goal https://www.firstwordpharma.com/node/1679605 

Original Article: Mid-stage study of AnaptysBio's anti-IL-33 antibody etokimab in atopic dermatitis fails to hit main goal https://www.firstwordpharma.com/node/1679605  $ANAB

NEXT ARTICLE

More From BioPortfolio on "Mid-stage study of AnaptysBio's anti-IL-33 antibody etokimab in atopic dermatitis fails to hit main goal https://www.firstwordpharma.com/node/1679605  $ANAB"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...